A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the non-inferiority of overall survival
XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as
Second-line therapy in Patient with Metastatic Colorectal Cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Epidemiological and Clinical Research Information Network